A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol

PURPOSE: Flavopiridol, the first clinically evaluated cyclin dependent kinase inhibitor, demonstrates activity in patients with refractory chronic lymphocytic leukemia, but prevalent and unpredictable tumor lysis syndrome (TLS) presents a major barrier to its broad clinical use. The purpose of this...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ji, Jia, Mould, Diane R., Blum, Kristie A., Ruppert, Amy S., Poi, Ming, Zhao, Yuan, Johnson, Amy J., Byrd, John C., Grever, Michael R., Phelps, Mitch A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3845832/
https://ncbi.nlm.nih.gov/pubmed/23300276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-1092
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak